incretin mimetics glp 1 agonists GLP-1s & Beyond: Understanding Mimetic Opportunities The incretin system: glucagon-like peptide-1

This remains to be investigated

Your doctor may recommend a care and treatment plan, including changing your dose or making dietary adjustments

doi: 10.1056/NEJMoa066254, PMID: [DOI] [PubMed] [Google Scholar] 10

This increases development complexity, extends commercialization timelines, and delays broader market access for innovative GLP-1 therapies

Semaglutide was the most cost-effective treatment compared to exenatide, dulaglutide, liraglutide, or no treatment in short-term analyses (approximately one and a half years) that assessed quality-adjusted life years and incremental cost-effectiveness ratios [135144]

Critics also highlight that brand-name GLP-1 manufacturers have secured extensive patent protection, averaging 19.5 patents per drug and 18.3 years of expected exclusivity, with over half of these patents focused on delivery devices rather than the drugs themselves [71]